Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT05463796
Official study title

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Study summary

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSamples

The study team can explain what participation involves.

Who it may be forCancer Risk · Cancer Predisposition Syndrome

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 17, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Dana-Farber Cancer Institute

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Other: Samples
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type): 1-Hereditary risk for cancer including
  • Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes
  • Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)
  • Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)
  • Hereditary Cancer Prediction Model-based elevated cancer risk
  • Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\&N cancer for example), etc.
  • Exposed High Risk including
  • Childhood cancer survivors with treatment exposures associated with increased risk of cancer
  • Adult cancer survivors with treatment exposures associated with increased risk of cancer
  • Documented high level exposure to group 1 IARC carcinogens
  • Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \>50, Smoking history of \>15 pack years, First-degree relative history of lung cancer or COPD
  • alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis
  • Precursor Lesions including
  • Breast: ductal/lobular carcinoma in situ (CIS) and atypical hyperplasia
  • GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia/adenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis
  • GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia/carcinoma in situ,
  • Lung: Adenomatous hyperplasia
  • H\&N: high-risk oral precancerous diseases
  • Skin: Class II melanocytic lesions. Squamous dysplasia
  • Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas
  • Thoracic: Lung nodules detected on screening CT that prompt further follow-up
  • GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia
  • Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.
  • FAMILY MEMBERS or healthy individuals
Reasons someone may not be able to joinExclusion criteria

There are no

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Dana Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 17, 2026. Always confirm current availability with the study team.

View original record ↗